NDATOPICALAEROSOL, FOAM
Approved
Oct 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
EVOCLIN (clindamycin phosphate) by PharmaIN is clinical pharmacology mechanism of action clindamycin is an antibacterial drug (see). Approved for acne vulgaris, bacterial vaginosis. First approved in 2004.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Clindamycin is an antibacterial drug (See). Pharmacokinetics Systemic absorption of clindamycin was estimated following a once-a-day intravaginal dose of one clindamycin phosphate vaginal suppository (equivalent to 100 mg clindamycin) administered to 11…
Indications (2)
Worked on EVOCLIN at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.